Affluent Medical SA (FR:CVX)
:CVX
Want to see FR:CVX full AI Analyst Report?
CVX Stock Chart & Stats
€3.01
-€0.01(-0.72%)
At close: 4:00 PM EST
€3.01
-€0.01(-0.72%)
Day’s Range― - ―
52-Week Range€1.16 - €5.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)9.49K
Market Cap
€209.64M
Enterprise Value€164.42M
Total Cash (Recent Filing)€1.76M
Total Debt (Recent Filing)€24.04M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding59,243,675
10 Day Avg. Volume9,769
30 Day Avg. Volume9,492
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)12.26
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside66.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€1.38M
Bulls Say, Bears Say
Bulls Say
Diversified Clinical PipelineAffluent Medical's portfolio spans structural heart, endovascular aneurysm sealing, and urinary incontinence devices. A multi-indication pipeline reduces reliance on a single program, spreads clinical and regulatory risk, and supports multiple potential commercialization pathways over the next 2–6 months to years.
Substantial Asset BaseReported balance-sheet commentary notes a substantial asset base. For a development-stage medtech, tangible and intangible assets (IP, equipment) provide strategic optionality for licensing, partnerships, or collateral in financing, helping sustain R&D progress while seeking regulatory milestones.
Prior Revenue ScalabilityHistorical scaling into 2024 indicates the company has previously translated development progress into some commercial or milestone revenue. This capability suggests organizational experience in moving toward revenue generation, which could matter as clinical programs progress toward commercialization.
Bears Say
Zero 2025 Revenue And Wider LossesReporting zero revenue in 2025 after prior scaling and materially wider net losses signals a major setback in commercial traction or milestone recognition. Persistently absent top-line inflows undermine self-funded R&D and increase reliance on external financing, constraining long-term program delivery.
Persistent Heavy Cash BurnConsistent negative operating and free cash flow indicates that reported losses are translating into real cash outflows. This persistent cash burn makes the company dependent on new financing to sustain trials and regulatory work, elevating dilution and execution risk over the medium term.
Deteriorated Leverage & Eroded EquityRising debt alongside collapsing equity has driven leverage sharply higher, reducing financial flexibility. For a development-stage device firm this raises refinancing risk, potentially increases borrowing costs, and limits ability to absorb clinical setbacks or fund multiple programs concurrently.
Affluent Medical SA News
CVX FAQ
What was Affluent Medical SA’s price range in the past 12 months?
Affluent Medical SA lowest stock price was €1.16 and its highest was €5.22 in the past 12 months.
What is Affluent Medical SA’s market cap?
Affluent Medical SA’s market cap is €209.64M.
When is Affluent Medical SA’s upcoming earnings report date?
Affluent Medical SA’s upcoming earnings report date is Sep 24, 2026 which is in 94 days.
How were Affluent Medical SA’s earnings last quarter?
Currently, no data Available
Is Affluent Medical SA overvalued?
According to Wall Street analysts Affluent Medical SA’s price is currently Undervalued.
Does Affluent Medical SA pay dividends?
Affluent Medical SA does not currently pay dividends.
What is Affluent Medical SA’s EPS estimate?
Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Affluent Medical SA have?
Affluent Medical SA has 59,243,675 shares outstanding.
What happened to Affluent Medical SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Affluent Medical SA?
Currently, no hedge funds are holding shares in FR:CVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Affluent Medical SA
Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavors encompass the creation of AI- and imaging-driven mini-robots, engineered for executing intricate medical procedures, as well as the development of biomimetic heart valves. Established on January 30, 2026, Carvolix S.A. maintains its headquarters in Aix-en-Provence, France.
CVX Stock 12 Month Forecast
Average Price Target
€5.00
▲(66.11% Upside)
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Implanet SA
―